Actively Recruiting

All Genders
ID05927467

Study of the Natural History of Alport Syndrome by Establishment of an International Database

Led by Institut National de la Santé Et de la Recherche Médicale, France · Updated on 2025-09-18

700

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Alport syndrome is a rare inherited condition that affects the kidneys, hearing, and eyes due to mutations in genes for type IV collagen chains in the kidney's filtering membrane. Researchers aim to better understand the natural history of this disease, including how kidney failure progresses, and to identify biomarkers that could predict kidney disease progression earlier than currently possible. The study also explores the impact of Alport syndrome on patients' education, work life, and treatment adherence, with collaboration across European countries and support from the French renal rare disease sector. This observational study involves creating a European database to collect detailed information on Alport syndrome patients. Data gathered includes kidney function measurements like estimated glomerular filtration rate (eGFR), urine analysis for blood and protein levels, hearing loss assessments, and eye examinations for related symptoms. The study also tracks blood pressure, treatment tolerance, and quality of life through questionnaires over multiple years. Participants will be followed through regular assessments at 1, 2, and 3 years to monitor kidney function, urine markers, hearing and eye health, blood pressure, and treatment safety. Researchers will also evaluate compliance with prescribed medications and the disease's overall impact on daily living. The study's goal is to collect comprehensive information to support future therapeutic trials and improve understanding of Alport syndrome progression.

CONDITIONS

Brief Title

Eurbio-Alport (RaDiCo Cohort) (RaDiCo Eurbio-Alport)

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of Alport syndrome based on electron microscopic kidney biopsy and/or molecular studies and/or abnormal type IV collagen expression on skin or kidney membranes
  • Signed informed consent
Not Eligible

You will not qualify if you...

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Monitoring

Duration - Up to 3 years

Participants are observed over time to collect information about the natural history of Alport Syndrome, including kidney function, urine bio-analysis, hypertension, hearing loss, and ocular symptoms.

Visits at 1 year, 2 years, and 3 years

Trial Site Locations

Total: 1 location

1

RaDiCo Eurbio-Alport

Paris, Île-de-France Region, France, 75012

Actively Recruiting

Loading map...

Research Team

L

Laurence Heidet, PHD

B

Bertrand Knebelmann, PHD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

European Alport Therapy Registry - European Initiative Towar...

Alport Syndrome

Actively Recruiting

1 location

Alport Syndrome Foundation Alport Patient Registry

Alport Syndrome

Actively Recruiting

1 location

A Randomized, Double-blind, Placebo-controlled Study to Eval...

Alport Syndrome

Actively Recruiting

60 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here